PMID- 28918212
OWN - NLM
STAT- MEDLINE
DCOM- 20190214
LR  - 20190215
IS  - 1532-8430 (Electronic)
IS  - 0022-0736 (Linking)
VI  - 51
IP  - 1
DP  - 2018 Jan-Feb
TI  - An alpha-glucosidase inhibitor could reduce T-wave alternans in type 2 diabetes 
      patients.
PG  - 21-26
LID - S0022-0736(17)30257-1 [pii]
LID - 10.1016/j.jelectrocard.2017.08.016 [doi]
AB  - BACKGROUND: We tested the hypothesis that an alpha-glucosidase inhibitor (alpha-GI), 
      miglitol, is effective in protecting the cardiovascular system in type 2 diabetes 
      mellitus (T2DM). METHODS: We studied 19 hospitalized heart disease patients with 
      T2DM in whom we performed continuous glucose monitoring, Holter 
      electrocardiogram, and ambulatory blood pressure (BP) monitoring simultaneously 
      for 48h. The alpha-GI miglitol was administered for half of the study period by a 
      cross-over fashion. T-wave alternans (TWA), a marker of future fatal arrhythmic 
      events, was also analyzed by Holter ECG. RESULTS: Of the 19 patients, the 
      measures of glucose variability were significantly lower during miglitol therapy 
      than in control period. BP variability was similar with/without miglitol. 
      However, TWA was significantly lower during the miglitol period compared to 
      control period (63+/-4.8 vs. 75.8+/-5.1muV, p=0.032). CONCLUSION: An alpha-GI, miglitol, 
      can reduce TWA by reducing the fluctuation of glucose in heart disease patients 
      with T2DM.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Eguchi, Kazuo
AU  - Eguchi K
AD  - Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical 
      University, Tochigi, Japan. Electronic address: ke112@jichi.ac.jp.
FAU - Komori, Takahiro
AU  - Komori T
AD  - Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical 
      University, Tochigi, Japan.
FAU - Saito, Toshinobu
AU  - Saito T
AD  - Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical 
      University, Tochigi, Japan.
FAU - Hoshide, Satoshi
AU  - Hoshide S
AD  - Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical 
      University, Tochigi, Japan.
FAU - Kario, Kazuomi
AU  - Kario K
AD  - Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical 
      University, Tochigi, Japan.
LA  - eng
SI  - UMIN-CTR/UMIN000015385
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170815
PL  - United States
TA  - J Electrocardiol
JT  - Journal of electrocardiology
JID - 0153605
RN  - 0 (Blood Glucose)
RN  - 0 (Glycoside Hydrolase Inhibitors)
RN  - 0V5436JAQW (miglitol)
RN  - 19130-96-2 (1-Deoxynojirimycin)
SB  - IM
MH  - 1-Deoxynojirimycin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Aged
MH  - Arrhythmias, Cardiac/*prevention & control
MH  - Blood Glucose/metabolism
MH  - Blood Pressure
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/physiopathology
MH  - Electrocardiography, Ambulatory/*drug effects
MH  - Female
MH  - Glycoside Hydrolase Inhibitors/pharmacology/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - Alpha-glucosidase inhibitor
OT  - Glycemic variability
OT  - T-wave alternans
EDAT- 2017/09/18 06:00
MHDA- 2019/02/15 06:00
CRDT- 2017/09/18 06:00
PHST- 2017/04/18 00:00 [received]
PHST- 2017/09/18 06:00 [pubmed]
PHST- 2019/02/15 06:00 [medline]
PHST- 2017/09/18 06:00 [entrez]
AID - S0022-0736(17)30257-1 [pii]
AID - 10.1016/j.jelectrocard.2017.08.016 [doi]
PST - ppublish
SO  - J Electrocardiol. 2018 Jan-Feb;51(1):21-26. doi: 
      10.1016/j.jelectrocard.2017.08.016. Epub 2017 Aug 15.